Characterization of E-cadherin expression in normal mucosa, dysplasia and adenocarcinoma of gastric cardia and its influence on prognosis
Hai-Ling Wang, Xue-Ke Zhao, Xin Song, Liu-Yu Li, Ling-Ling Lei, Rui-Hua Xu, Wen-Li Han, Li-Dong Wang, State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Fu-You Zhou, Department of Thoracic Surgery and Tumor Prevention Treatment, Anyang Tumor Hospital, Anyang 455000, Henan Province, China
Gai-Rong Huang, Li Li, Department of Geriatrics, Henan Provincial People’s Hospital, Zhengzhou 450003, Henan Province, China
Qi-De Bao, Department of Oncology, Anyang District Hospital, Anyang 455000, Henan Province, China
Hai-Jun Yang, Department of Pathology, Anyang Tumor Hospital, Anyang 455000, Henan Province, China
Ai-Li Li, Department of Pathology, Linzhou Tumor Hospital, Linzhou 456500, Henan Province, China
Xian-Zeng Wang, Department of Thoracic Surgery, Linzhou People's Hospital, Linzhou 456500, Henan Province, China
Jing-Li Ren, Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Author contributions: Wang LD and Wang HL designed the study and wrote the paper; Zhao XK, Song X and Huang GR performed data collection; Bao QD, Lei LL and Yang HJ conducted follow-up of the patients; Li LY, Li L and Xu RH performed the tissue microarray; Zhou FY and Li AL performed the immunohistochemical analysis; Wang XZ, Han WL and Ren JL contributed to data analysis; Wang LD revised the manuscript.
Supported by National Natural Science Foundation of China, No. 81872032, and No. U1804262; and National Key R&D Program of China, No. 2016YFC0901403.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Zhengzhou University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no potential conflicts of interest to disclose.
Data sharing statement: No additional data are available.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Dong Wang, MD, PhD, Professor, State Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, No. 40 Daxue Road, Zhengzhou 450052, Henan Province, China. firstname.lastname@example.org
Received: September 6, 2021
Peer-review started: September 6, 2021
First decision: November 8, 2021
Revised: November 18, 2021
Accepted: December 8, 2021
Article in press: December 8, 2021
Published online: January 15, 2022